Company intelligence / Profile preview
Priothera
Dublin, Irelandpriothera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Priothera is conducting a pivotal MO-TRANS global Phase 2b/3 study evaluating mocravimod in AML patients undergoing allogeneic hematopoietic cell transplant (HCT). First patients were enrolled in January 2023, with topline results expected in 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesS1P receptor modulators
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Priothera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Priothera.